Hookipa Pharma (NASDAQ:HOOK) Given New $7.00 Price Target at JMP Securities

Hookipa Pharma (NASDAQ:HOOK) had its target price reduced by JMP Securities from $24.00 to $7.00 in a research report report published on Thursday morning,Benzinga reports. JMP Securities currently has a market outperform rating on the stock.

Separately, Royal Bank of Canada reduced their price objective on Hookipa Pharma from $50.00 to $48.00 and set an “outperform” rating for the company in a report on Friday, November 15th.

Hookipa Pharma Stock Performance

Shares of HOOK stock opened at $2.15 on Thursday. The company’s 50-day moving average is $3.84 and its 200 day moving average is $5.50. Hookipa Pharma has a one year low of $2.08 and a one year high of $11.30. The company has a market capitalization of $25.93 million, a price-to-earnings ratio of -0.58 and a beta of 0.84.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Virtu Financial LLC bought a new position in shares of Hookipa Pharma in the first quarter worth about $31,000. Renaissance Technologies LLC raised its stake in Hookipa Pharma by 38.4% during the second quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock valued at $179,000 after purchasing an additional 83,800 shares in the last quarter. Ikarian Capital LLC bought a new position in shares of Hookipa Pharma in the 3rd quarter valued at about $228,000. Finally, Acadian Asset Management LLC boosted its holdings in shares of Hookipa Pharma by 12.3% in the 2nd quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock worth $586,000 after purchasing an additional 108,844 shares during the period. 63.88% of the stock is owned by hedge funds and other institutional investors.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.